At the time of writing, Kymera Therapeutics Inc [KYMR] stock is trading at $30.13, down -4.17%. An important factor to consider is whether the stock is rising or falling in short-term value. The KYMR shares have gain 1.28% over the last week, with a monthly amount glided 4.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup started tracking the stock with Buy rating on March 13, 2025, and set its price target to $52. On December 10, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $60 on the stock. BMO Capital Markets started tracking the stock assigning a Market Perform rating and suggested a price target of $55 on December 06, 2024. Wells Fargo upgraded its rating to a Overweight but $57 remained the price target by the analyst firm on December 02, 2024. Stephens started tracking with a Overweight rating for this stock on November 18, 2024, and assigned it a price target of $65.
For the past year, the stock price of Kymera Therapeutics Inc fluctuated between $19.44 and $53.27. Currently, Wall Street analysts expect the stock to reach $55.33 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $30.13 at the most recent close of the market. An investor can expect a potential return of 83.64% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
According to Kymera Therapeutics Inc [NASDAQ:KYMR], the company’s sales were 58.88M for trailing twelve months, which represents an 114.83% jump. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -4.72%, Pretax Profit Margin comes in at -4.09%, and Net Profit Margin reading is -4.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.3 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Kymera Therapeutics Inc [NASDAQ:KYMR] has a current ratio of 8.49. On the other hand, the Quick Ratio is 8.49, and the Cash Ratio is 1.53. Considering the valuation of this stock, the price to sales ratio is 33.32, the price to book ratio is 2.50.
Transactions by insiders
Recent insider trading involved Chiniara Ellen, Chief Legal Officer, that happened on Mar 03 ’25 when 2241.0 shares were sold. Chief Operating Officer, Chadwick Jeremy G completed a deal on Mar 03 ’25 to sell 1383.0 shares. Meanwhile, Chief Financial Officer Jacobs Bruce N. sold 7035.0 shares on Mar 03 ’25.
